Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Arcus Biosciences, Inc. (RCUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update • Presented data from the ongoing ARC-7 Phase 2 trial in non-small cell lung cancer at American Society of Clinical Oncology ; Fc-silent anti-TIGIT monoclonal antibody domvanalimab continued to demonstrate clinically meaningful improvements over anti-PD-1 monotherapy across all measures evaluated, including progression-free survival, overall response rate, and duration of response • Initiated the dose-expansion phase of the Phase 1b ARC-20 study of AB521, a potential best-in-class HIF-2a inhibitor, in clear-cell renal cell carcinoma patients at a dose of 100 mg daily; pharmacokinetic, pharmacodynamic and safety data, along with any preliminary signs of anti-tumor activity from the d..."
06/16/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF JUNE 15, 2023 A. Cash Compensation Annual cash retainers each paid quarterly, in arrears, as follows: 1. Retainer for each non-employee member of the Board: $45,000 2. Additional retainer for Lead Independent Director: $25,000 3. Additional retainer for Chair of Audit Committee: $20,000 4. Additional retainer for Chair of Compensation Committee: $15,000 5. Additional retainer for Chair of Nominating and Corporate Governance Committee: $10,000 6. Additional retainer for non-Chair members of Audit Committee: $10,000 7. Additional retainer for non-Chair members of Compensation Committee: $7,500 8. Additional retainer for non-Chair member of Nominating and Corporate Governance Committee: $5,000 B. E..."
05/15/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update • Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. • The third dose-escalation cohort of ARC-20 for AB521, a potential best-in-class HIF-2a inhibitor, is enrolling; the dose-expansion stage of ARC-20 and a Phase 2 combination study in clear-cell renal cell carcinoma patients are expected to begin in the third quarter. • Three new drug candidates are expected to advance into the clinic in 2023 and early 2024. • With $1.0 billion in cash, cash equivalents and marketable securities and funding into 2026, Arcus is well-positioned to advance its pipeline. HAYWARD, Calif. – – May 9, 2023 – ..."
03/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/28/2023 8-K Quarterly results
12/19/2022 8-K Quarterly results
11/28/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
10/11/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Investor Rights Agreement",
"Amendment No. 1 to Investor Rights Agreement"
08/03/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/23/2022 8-K Quarterly results
Docs: "Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update • Presentations of randomized data for domvanalimab and etrumadenant in 1L PD-L1 high non-small cell lung cancer and quemliclustat in pancreatic cancer are planned for 2H:22 • Initial pharmacokinetic /pharmacodynamic data for AB521, Arcus’s HIF-2a inhibitor, in healthy volunteers confirm its potential to have an improved clinical profile compared to the approved HIF-2a inhibitor; data to be presented at a conference this March • First patient dosed in PACIFIC-8, a registrational, Phase 3 study evaluating domvanalimab plus durvalumab in unresectable, Stage 3 NSCLC with AstraZeneca; this represents the second Phase 3 study to be initiated for domvanalimab in NSCLC ..."
12/21/2021 8-K Other Events  Interactive Data
11/18/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
11/08/2021 8-K Quarterly results
Docs: "Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab  Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to that of zimberelimab alone in a second interim analysis of ARC-7, our randomized Phase 2 study in first-line metastatic non-small cell lung cancer  Gilead Sciences has initiated its opt-in review process for our anti-TIGIT program o If the option is exercised and closed, Arcus would receive a $275 million opt-in payment, and the parties would share equally R&D expenses related to the anti-TIGIT program o A decision is expected prior to the end of 2021  Updated data from ARC-8, a Phase 1study of quemliclustat, our small molecule anti-CD73 inhibitor for pancreat..."
08/11/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
07/19/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Statement"
06/07/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/26/2021 8-K Quarterly results
04/16/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
02/01/2021 8-K Quarterly results
01/06/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/18/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/05/2020 8-K Quarterly results
Docs: "Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates"
10/01/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
07/13/2020 8-K Quarterly results
07/07/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy